LuciVos (Ivosidenib) 250mg Tablets — IDH1 Inhibitor Generic for AML | Laos | GLT

Generic Information: LuciVos (Ivosidenib) by Lucius

LuciVos is Lucius Pharmaceuticals' generic version of ivosidenib, the first-in-class oral IDH1 inhibitor behind the originator brand Tibsovo. Each box supplies 60 tablets of 250 mg — a full month of once-daily therapy in a single container. Manufactured in Laos by one of the country's longest-established generic exporters, LuciVos gives IDH1-mutated AML patients a dependable, budget-sustainable route to a targeted medicine that would otherwise cost orders of magnitude more through Western channels.

Lucius Pharmaceuticals runs a broad oncology and specialty portfolio from its Lao facilities, with products distributed across Southeast Asia and beyond; the company's Luci-branded line is known for consistent packaging, batch documentation, and straightforward export logistics.

What Is LuciVos (Ivosidenib) 250 mg?

LuciVos is an oral film-coated tablet containing exactly 250 mg of ivosidenib per tablet — the same strength patients would take under the originator's label. The 60-tablet presentation matches a standard treatment month, so a prescription cycle translates directly into one box. As a generic, it must deliver the same active ingredient and performance; what differs is the price and the accessibility that comes with it.

How Does LuciVos (Ivosidenib) Block IDH1?

The drug selectively inhibits the mutant isocitrate dehydrogenase-1 enzyme that produces the oncometabolite 2-hydroxyglutarate (2-HG). In IDH1-mutated leukemia, 2-HG acts like a handbrake on cell maturation; ivosidenib releases it. Blasts that could neither differentiate nor die regain both abilities, which translates clinically into remissions in relapsed/refractory patients who had few remaining options. Because the target is a metabolic enzyme unique to the tumor, the mechanism simply does not exist in other AML treatments — combination partners like azacitidine are therefore complementary rather than redundant.

Indications of LuciVos

• Relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, confirmed by validated genomic testing.
• Newly diagnosed IDH1-mutated AML in patients unsuited to intensive chemotherapy, where combination with a hypomethylating agent is clinically appropriate.
• Previously treated IDH1-mutated cholangiocarcinoma, at the treating oncologist's discretion, following the originator's evidence base.

Dosage of LuciVos (Ivosidenib)

One 250 mg tablet once daily, swallowed whole with water at approximately the same time each day, with or without food — avoiding high-fat meals and never splitting the tablet. Continue until disease progression or limiting toxicity. Essential monitoring mirrors the originator protocol: baseline and serial ECG for QTc, electrolytes, and frequent blood counts, plus early recognition of differentiation syndrome (fever, breathlessness, rapid weight gain), which is treated with corticosteroids. Physicians adjust dosing for interacting medications and adverse reactions.

Side Effects with LuciVos

Expect the class-typical profile of the molecule itself: fatigue, neutropenia and leukopenia, diarrhea, peripheral edema, nausea, vomiting, stomatitis, abdominal pain, and QTc-interval prolongation. Serious but manageable risks include differentiation syndrome and clinically significant QT prolongation — both of which are screened for proactively in well-run treatment programs. Any fever, chest tightness, or breathlessness during therapy warrants immediate medical contact.

Storage Instructions for LuciVos

Keep the box below 30°C, tightly closed, dry, and away from direct sunlight; no cold chain is involved. Store all medicines out of children's reach, and take expired tablets to a pharmacy for disposal.

Why Choose LuciVos via GLT?

The originator's Western list price is among the highest in hematology-oncology; LuciVos delivers the identical 250 mg ivosidenib tablet at a small fraction of that cost, with the manufacturer's batch records and Lao regulatory documentation behind it. GIVE LIFE TIME LIMITED (GLT) sources directly from Lucius Pharmaceuticals, verifies every batch, and ships worldwide to both institutions and families — so treatment continuity never depends on an unaffordable invoice.

How to Order LuciVos (Ivosidenib)

To order LuciVos (ivosidenib 250 mg, 60 tablets), contact GIVE LIFE TIME LIMITED (GLT). We serve hospital procurement, licensed pharmacy wholesalers, physician buyers, and individual patients and their families. Reach us on WhatsApp at +86 15234153837 or email [email protected] for availability, pricing, and shipping to your country.

FAQ: LuciVos Ivosidenib Generic

Q: Who manufactures LuciVos?
A: Lucius Pharmaceuticals, a Laos-based generic manufacturer with an established oncology export portfolio.

Q: What pack does LuciVos come in?
A: 60 tablets of 250 mg per box — a full month of once-daily dosing.

Q: Is LuciVos bioequivalent in practice?
A: It contains the same active ingredient at the same strength; GLT supplies manufacturer documentation with every order.

Q: Which patients benefit?
A: Those whose leukemia or bile-duct cancer tests positive for an IDH1 mutation, especially after relapse or when intensive chemotherapy is unsuitable.

Q: How do I order LuciVos?
A: WhatsApp +86 15234153837 or email [email protected], and GLT will confirm documentation and delivery options.